- Conditions
- End Stage Renal Disease on Dialysis
- Interventions
- Fight Fatigue, Attention Control
- Behavioral · Other
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 313–336
of 853
matching trials from the live ClinicalTrials.gov search.
- Conditions
- End Stage Liver Disease, Decompensated Cirrhosis of Liver
- Interventions
- Palliative Care
- Other
- Lead sponsor
- Albert Einstein Healthcare Network
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 1,494 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 15 more
- Conditions
- Focal Segmental Glomerulosclerosis, Nephrotic Syndrome, End Stage Renal Disease, Kidney Failure, Unexplained Proteinuria
- Interventions
- Not listed
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- Not listed
- Enrollment
- 2,050 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1996 – 2035
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- End Stage Kidney Disease, End Stage Renal Disease, Acute Kidney Injury
- Interventions
- Intermittent Renal Replacement Therapy using the Tablo Hemodialysis System, Intermittent Renal Replacement Therapy using Conventional Hemodialysis Systems
- Device
- Lead sponsor
- Outset Medical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 458 participants
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Orlando, Florida • Fort Worth, Texas
- Conditions
- Multidrug Resistant Organisms, Healthcare Associated Infections
- Interventions
- Quaternary ammonium, Bleach, Quaternary ammonium and UV-C light, Bleach and UV-C light
- Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- Not listed
- Enrollment
- 21,395 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 9
- States / cities
- Burlington, North Carolina • Chapel Hill, North Carolina • Durham, North Carolina + 3 more
- Conditions
- End-Stage Renal Disease
- Interventions
- BalanceWise-PD, Attention control
- Behavioral
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- End Stage Renal Failure
- Interventions
- Lower sodium intervention, Progressive Challenge to Post Dialysis Weight
- Behavioral · Other
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 2
- States / cities
- Ann Arbor, Michigan • Livonia, Michigan
- Conditions
- End Stage Liver Disease
- Interventions
- cardiopulmonary exercise testing
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Heart Failure, Cardiomyopathy
- Interventions
- Not listed
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Cranial Nerve Disorder, Head and Neck Carcinoma, Oropharyngeal Carcinoma
- Interventions
- Methylprednisolone, Prednisone, Quality-of-Life Assessment, Questionnaire Administration
- Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Liver Diseases, End Stage Liver Disease, Frailty
- Interventions
- Nokia GO Wearable StepTracker, Medication Reminder, Weekly Check-in appointment with study team or provider
- Device · Other
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 21 Years to 95 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- End Stage Renal Disease on Dialysis, Home Dialysis
- Interventions
- Not listed
- Lead sponsor
- Satellite Healthcare
- Other
- Eligibility
- Not listed
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- San Jose, California
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Carotuximab (TRC105), Sorafenib
- Drug
- Lead sponsor
- Tracon Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Cleveland, Ohio • Houston, Texas
- Conditions
- End-Stage Renal Disease
- Interventions
- ESA Dose Adjustment per standard Anemia Management Protocol, ESA Dose Adjustment per "Smart Anemia Manager" Algorithm
- Other
- Lead sponsor
- University of Louisville
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- End Stage Renal Disease, Hypertension, Extracellular Volume Overload, Intradialytic Hypotension
- Interventions
- IBPS-Guided Ultrafiltration
- Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Type 2 Diabetes, End Stage Renal Disease
- Interventions
- Placebo, Sitagliptin
- Drug
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years to 70 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Recurrent Ovarian Cancer, Fallopian Tube Cancer
- Interventions
- Usual Care Educational Website, Prototype System
- Behavioral
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Acute Lung Injury, End Stage Lung Disease
- Interventions
- Voxelotor
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Muscular Dystrophy, Duchenne, Muscular Dystrophies, Muscular Disorders, Atrophic, Muscular Diseases, Musculoskeletal Disease, Neuromuscular Diseases, Nervous System Diseases, Genetic Diseases, X-Linked, Genetic Diseases, Inborn
- Interventions
- Ataluren, PLACEBO
- Drug
- Lead sponsor
- PTC Therapeutics
- Industry
- Eligibility
- 5 Years and older · Male only
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Los Angeles, California • Oakland, California + 19 more
- Conditions
- Kidney Failure, Chronic, Multiple Myeloma
- Interventions
- Combined bone marrow and kidney transplant
- Procedure
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hepatic Encephalopathy, Liver Failure, Hepatitis, Chronic, Liver Cirrhosis
- Interventions
- MARS, Standard Medical Therapy
- Device · Drug
- Lead sponsor
- Vantive Health LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2004
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • San Diego, California • Chicago, Illinois + 3 more
- Conditions
- Chronic Kidney Diseases, Major Depressive Disorder, End Stage Kidney Disease (ESRD)
- Interventions
- Bupropion, Behavioral activation therapy, Placebo, Clinical Management
- Drug · Behavioral · Other
- Lead sponsor
- Stony Brook University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 4
- States / cities
- Stony Brook, New York • Dallas, Texas • Seattle, Washington
- Conditions
- Improve Endothelial Function and Decrease Vascular Stenosis
- Interventions
- Sildenafil, Placebo
- Drug · Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years to 99 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Calciphylaxis
- Interventions
- Tocilizumab
- Drug
- Lead sponsor
- Boston Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2030
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts